Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile – – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral presentation at the 66th American Society of Hematology ...

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been ...